- Home
- NXL vs KPLT Comparison
NXL vs KPLT Comparison
Compare NXL & KPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- KPLT
- Stock Information
- Founded
- NXL 2010
- KPLT 2012
- Country
- NXL United States
- KPLT United States
- Employees
- NXL N/A
- KPLT N/A
- Industry
- NXL Medical Specialities
- KPLT Diversified Commercial Services
- Sector
- NXL Health Care
- KPLT Consumer Discretionary
- Exchange
- NXL Nasdaq
- KPLT Nasdaq
- Market Cap
- NXL 24.2M
- KPLT 35.6M
- IPO Year
- NXL 2022
- KPLT N/A
- Fundamental
- Price
- NXL $1.17
- KPLT $7.38
- Analyst Decision
- NXL Strong Buy
- KPLT Hold
- Analyst Count
- NXL 1
- KPLT 2
- Target Price
- NXL $5.00
- KPLT $12.00
- AVG Volume (30 Days)
- NXL 121.2K
- KPLT 18.8K
- Earning Date
- NXL 05-20-2025
- KPLT 05-15-2025
- Dividend Yield
- NXL N/A
- KPLT N/A
- EPS Growth
- NXL N/A
- KPLT N/A
- EPS
- NXL N/A
- KPLT N/A
- Revenue
- NXL $168,721.00
- KPLT $247,194,000.00
- Revenue This Year
- NXL $79.59
- KPLT $20.12
- Revenue Next Year
- NXL $334.65
- KPLT $13.19
- P/E Ratio
- NXL N/A
- KPLT N/A
- Revenue Growth
- NXL 52.35
- KPLT 11.56
- 52 Week Low
- NXL $0.53
- KPLT $5.08
- 52 Week High
- NXL $4.49
- KPLT $23.54
- Technical
- Relative Strength Index (RSI)
- NXL 22.27
- KPLT 39.27
- Support Level
- NXL $1.75
- KPLT $6.72
- Resistance Level
- NXL $1.39
- KPLT $7.55
- Average True Range (ATR)
- NXL 0.13
- KPLT 0.43
- MACD
- NXL -0.05
- KPLT 0.11
- Stochastic Oscillator
- NXL 0.01
- KPLT 40.00
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.